Amarin Corp Plcuk (AMRN) Other Non Operating Income (2010 - 2026)
Amarin Corp Plcuk (AMRN) posted quarterly Other Non Operating Income of $188000.0 for Q1 2026, down 25.69% YoY from $253000.0 in Q1 2025, and down 93.53% sequentially from $2.9 million in Q4 2025.
Amarin Corp Plcuk (AMRN) Other Non Operating Income (2010 - 2026) Analysis & Trends
Amarin Corp Plcuk has disclosed Other Non Operating Income across 17 years of filings, most recently posting $188000.0 for Q1 2026.
- In Q1 2026, Other Non Operating Income fell 25.69% year-over-year to $188000.0; the TTM figure through Mar 2026 stood at $3.2 million (up 3668.89% YoY), while the FY2025 annual figure was $3.3 million, up 172.77% from the prior year.
- Other Non Operating Income slipped to $188000.0 in Q1 2026, from $2.9 million in the prior quarter.
- Over the last five years, Other Non Operating Income for AMRN reached as high as $3.0 million in Q2 2023 and fell as low as -$2.3 million in Q2 2022.
- The 5-year median for Other Non Operating Income is $205000.0 (2025), against an average of $352352.9.
- The widest YoY moves for Other Non Operating Income: up 1320.45% in 2022, down 1080.63% in 2022.
- A 5-year view of Other Non Operating Income shows it stood at $1.2 million in 2022, then sank by 182.32% to -$1.0 million in 2023, then advanced by 26.82% to -$753000.0 in 2024, then surged by 485.66% to $2.9 million in 2025, then sank by 93.53% to $188000.0 in 2026.
- According to Business Quant data, Other Non Operating Income over the past three periods registered $188000.0, $2.9 million, and $205000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Amarin Corp Plcuk | 5.17 Bn | 5.00 Bn | 17.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 188,000.00 |
| Dec 31, 2025 | 2.90 Mn |
| Sep 30, 2025 | 205,000.00 |
| Jun 30, 2025 | -85,000.00 |
| Mar 31, 2025 | 253,000.00 |
| Dec 31, 2024 | -753,000.00 |
| Sep 30, 2024 | 265,000.00 |
| Jun 30, 2024 | 145,000.00 |
| Mar 31, 2024 | 1.55 Mn |
| Dec 31, 2023 | -1.03 Mn |
| Sep 30, 2023 | -575,000.00 |
| Jun 30, 2023 | 3.04 Mn |
| Mar 31, 2023 | 624,000.00 |
| Dec 31, 2022 | 1.25 Mn |
| Sep 30, 2022 | 511,000.00 |
| Jun 30, 2022 | -2.26 Mn |
| Mar 31, 2022 | -246,000.00 |
| Dec 31, 2021 | 88,000.00 |
| Sep 30, 2021 | -57,000.00 |
| Jun 30, 2021 | -191,000.00 |